FARP2

Across TCGA pan-cancer cohorts, FARP2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FARP2 data layer compared with 26 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FARP2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated FARP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

LUAD, UCEC, and PDAC are the cancer types where FARP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	1.000	0.921	.001	34	view →
UCEC	DFS	Tertile	All	1.000	0.808	.001	32	view →
PDAC	OS	Median	III,IV	0.968	0.331	<.001	30	view →
CCRCC	OS	Tertile	All	1.000	0.905	.017	14	view →
LSCC	OS	Median	III,IV	0.680	0.996	.021	1	view →
GBM	OS	Median	All	0.664	0.845	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FARP2–LUAD (OS)

Open the LUAD breakdown →